Frontiers in Genetics,
Journal Year:
2023,
Volume and Issue:
14
Published: Sept. 1, 2023
Background:
Pancreatic
cancer
(PC)
is
a
deadly
disease.
The
tumor
microenvironment
(TME)
participates
in
PC
oncogenesis.
This
study
focuses
on
the
assessment
of
prognostic
and
treatment
utility
TME-associated
genes
PC.
Methods:
After
obtaining
differentially
expressed
TME-related
genes,
univariate
multivariate
Cox
analyses
least
absolute
shrinkage
selection
operator
(LASSO)
were
performed
to
identify
related
prognosis,
risk
model
was
established
evaluate
scores,
based
Cancer
Genome
Atlas
(TCGA)
data
set,
it
validated
by
external
sets
from
Gene
Expression
Omnibus
(GEO)
Clinical
Proteomic
Tumor
Analysis
Consortium
(CPTAC).
Multiomics
adopted
explore
potential
mechanisms,
discover
novel
targets,
assess
sensitivities
immunotherapy
chemotherapy.
Results:
Five
namely,
FERMT1,
CARD9,
IL20RB,
MET,
MMP3,
identified
score
formula
constructed.
Next,
their
mRNA
expressions
verified
normal
pancreatic
cells.
Multiple
algorithms
confirmed
that
displayed
reliable
ability
prognosis
prediction
an
independent
factor,
indicating
high-risk
patients
had
poor
outcomes.
Immunocyte
infiltration,
gene
set
enrichment
analysis
(GSEA),
single-cell
all
showed
strong
relationship
between
immune
mechanism
low-risk
samples.
could
predict
sensitivity
some
chemotherapy
regimens,
which
included
oxaliplatin
irinotecan.
Various
latent
targets
(LAG3,
TIGIT,
ARID1A)
addressed
mutation
landscape
model.
Conclusion:
can
reflect
functions
as
biomarkers
for
therapy.
Discover Oncology,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: March 31, 2024
Abstract
Objective
AT-rich
interaction
domain
1A
(ARID1A)
mutant
tumors
show
active
anti-tumor
immune
response,
which
is
the
potential
indication
of
immunotherapy.
However,
relationship
between
heterogeneous
ARID1A
expression
and
response
immunotherapy
efficacy
in
colorectal
cancer
(CRC)
still
unclear.
Methods
We
collected
1113
cases
patients
with
stage
I-IV
CRC
who
underwent
primary
resection
at
Harbin
Medical
University
Cancer
Hospital.
tissues
was
assessed
via
immunohistochemistry
(IHC).
CD8,
CD163
FOXP3
were
stained
by
IHC
to
identify
landscape.
Clinicopathological
features
compared
using
statistical
tests
like
Wilcoxon-Mann–Whitney
test
or
χ2
tests.
Kaplan–Meier
survival
analysis
log-rank
employed.
Results
Heterogeneous
categorized
into
integrity
expression,
complete
deficiency
(cd-ARID1A),
partial
(pd-ARID1A),
clonal
(cld-ARID1A).
ARID1A-deficient
significant
association
dMMR
(P
value
<
0.001).
Patients
deficiency,
ARID1A-proficient
patients,
exhibited
increased
infiltration
levels
CD8
+
P
0.0001),
0.001),
0.001).cells
within
tumor
tissue.
different
subgroups,
only
samples
showed
a
higher
abundance
lymphocyte
infiltration.
In
ARID1A-clonal
tumor,
patterns
three
cell
types
comparable
those
patients.
related
prognosis
immunotherapythe
Conclusion
accompanied
do
not
benefit
from
treatment
checkpoint
inhibitors
(ICIs).
Cells,
Journal Year:
2025,
Volume and Issue:
14(9), P. 632 - 632
Published: April 24, 2025
The
efficacy
of
immunotherapy
in
pancreatic
ductal
adenocarcinoma
(PDAC)
remains
limited.
tumor
microenvironment
(TME),
characterized
by
the
accumulation
suppressive
myeloid
cells
including
neutrophils,
attributes
to
resistance
PDAC.
IgA
monoclonal
antibodies
(mAbs)
can
activate
neutrophils
kill
cells;
this
be
further
enhanced
blocking
immune
checkpoint
CD47.
In
study,
we
investigated
potential
therapeutic
strategy
for
We
determined
expression
tumor-associated
antigens
(TAAs)
on
PDAC
cell
lines
and
fresh
patient
samples,
results
showed
that
TAAs
epithelial
adhesion
molecule
(EpCAM),
trophoblast
surface
antigen
2
(TROP2)
mucin-1
(MUC1),
as
well
CD47
were
consistently
expressed
line
with
this,
mAbs
against
EpCAM
lyse
various
cells,
which
augmented
addition
blockade.
addition,
observed
present
tumors
receptor
IgA.
conclusion,
our
indicate
a
combination
mAb
blockade
is
promising
preclinical
treatment
PDAC,
merits
investigation.
Cancers,
Journal Year:
2023,
Volume and Issue:
15(8), P. 2354 - 2354
Published: April 18, 2023
An
overabundance
of
desmoplasia
in
the
tumour
microenvironment
(TME)
is
one
defining
features
that
influences
pancreatic
ductal
adenocarcinoma
(PDAC)
development,
progression,
metastasis,
and
treatment
resistance.
Desmoplasia
characterised
by
recruitment
activation
fibroblasts,
heightened
extracellular
matrix
deposition
(ECM)
reduced
blood
supply,
as
well
increased
inflammation
through
an
influx
inflammatory
cells
cytokines,
creating
intrinsically
immunosuppressive
TME
with
low
immunogenic
potential.
Herein,
we
review
development
PDAC,
drivers
initiate
and/or
sustain
progression
disease
complex
interwoven
nature
cellular
acellular
components
come
together
to
make
PDAC
most
aggressive
difficult
treat
cancers.
We
challenges
delivering
drugs
into
fortress
tumours
concentrations
are
therapeutic
due
presence
a
highly
fibrotic
TME.
Taken
together,
present
further
support
for
continued/renewed
efforts
focusing
on
aspects
extremely
dense
improve
efficacy
therapy
better
patient
outcomes.
Pharmaceutics,
Journal Year:
2022,
Volume and Issue:
14(10), P. 2033 - 2033
Published: Sept. 24, 2022
Immunotherapy
has
dramatically
changed
prognosis
for
patients
with
malignant
tumors.
However,
as
a
non-immunogenic
tumor,
pancreatic
ductal
adenocarcinoma
(PDAC)
low
response
to
immunotherapy.
Factors
that
contribute
the
inefficiency
of
PDAC
immunotherapy
include
tumor
microenvironment
(TME)
and
its
dense
stroma,
which
acts
barrier
drug
delivery
immune
cell
infiltration.
Recent
studies
have
shown
nanoparticle-based
therapeutic
strategies
more
promising
applications
in
improving
reversing
immunosuppressive
TME
PDAC.
Therefore,
nanomaterial-based
approaches
are
expected
enhance
effectiveness
improve
Here,
we
outline
status
dilemma
immunotherapy,
summarize
latest
advances
treatment
efficacy
Frontiers in Genetics,
Journal Year:
2023,
Volume and Issue:
14
Published: Sept. 1, 2023
Background:
Pancreatic
cancer
(PC)
is
a
deadly
disease.
The
tumor
microenvironment
(TME)
participates
in
PC
oncogenesis.
This
study
focuses
on
the
assessment
of
prognostic
and
treatment
utility
TME-associated
genes
PC.
Methods:
After
obtaining
differentially
expressed
TME-related
genes,
univariate
multivariate
Cox
analyses
least
absolute
shrinkage
selection
operator
(LASSO)
were
performed
to
identify
related
prognosis,
risk
model
was
established
evaluate
scores,
based
Cancer
Genome
Atlas
(TCGA)
data
set,
it
validated
by
external
sets
from
Gene
Expression
Omnibus
(GEO)
Clinical
Proteomic
Tumor
Analysis
Consortium
(CPTAC).
Multiomics
adopted
explore
potential
mechanisms,
discover
novel
targets,
assess
sensitivities
immunotherapy
chemotherapy.
Results:
Five
namely,
FERMT1,
CARD9,
IL20RB,
MET,
MMP3,
identified
score
formula
constructed.
Next,
their
mRNA
expressions
verified
normal
pancreatic
cells.
Multiple
algorithms
confirmed
that
displayed
reliable
ability
prognosis
prediction
an
independent
factor,
indicating
high-risk
patients
had
poor
outcomes.
Immunocyte
infiltration,
gene
set
enrichment
analysis
(GSEA),
single-cell
all
showed
strong
relationship
between
immune
mechanism
low-risk
samples.
could
predict
sensitivity
some
chemotherapy
regimens,
which
included
oxaliplatin
irinotecan.
Various
latent
targets
(LAG3,
TIGIT,
ARID1A)
addressed
mutation
landscape
model.
Conclusion:
can
reflect
functions
as
biomarkers
for
therapy.
